MICs, MPCs and PK/PDs: A match (sometimes) made in hosts

Expert Review of Respiratory Medicine

Volumn 1, Issue 1, 2007, Pages 7-16

  Hesje, Christine K ^a   Tillotson, Glenn S ^b   Blondeau, Joseph M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Replidyne Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48049096635     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.1.7     Document Type: Article

References (31)

1. Johnson CC. In vitro testing: correlations of bacterial susceptibility, body fluid levels and effectiveness of antibacterial therapy. In: Antibiotics in Laboratory Medicine. Lorian V (Ed.). Williams & Wilkins, MA, USA. 813–834 (1996).
2. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 1756–1758 (1999).
3. Firsch AW, Tripp JT, Barrett CD Jr, Pidgeon BE. Specific polysaccaride content of pneumoni lungs. J. Exp. Med. 76, 505–510 (1942).
4. Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 16 (Suppl. 3), 1–19 (2004).
5. Hansen G, Metzler KL, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47 (1), 440–441 (2003).
6. Smith H, Nichol KA, Hoban DJ, Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51, 1323–1325 (2003).
7. Benet LZ, Sheiner LB. General Principals (Introduction). In: The Pharmacological Basis of Therapeutics. Gillman AG, Goodman L, Rall TW, Murad F (Eds). MacMillan Publishing Company, NY, USA. 1 (1985).
8. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32 (Suppl. 1), S39 –S46 (2001).
9. Drusano GL, Preston SL, Owens RC Jr, Ambrose PG. Fluoroquinolone pharmacodynamics (correspondence). Clin. Infect. Dis. 33, 2091–2092 (2001).
10. Schentag JJ, Gilliland KK, Paladino JA. Fluoroquinolone pharmacodynamics (reply). Clin. Infect. Dis. 33, 2092–2096 (2001).
11. Lees P, Concordet D, Aliabadi FS, Toutain PL. Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. In: Antimicrobial Resistance in Bacteria of Animal Origin. Aarestrap FM (Ed). ASM Press, DC, USA. Chapter 5 (2006).
12. Zinner SH, Lubenko IY, Gilbert DN, Simmons K, Zhao X, Drlica K. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 52, 616–622 (2003).
13. Metzler KL, Hansen G, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24, 161–167 (2004).
14. Olofsson SK, Marcusson LL, Komp Lindgren P, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57 (6), 1116–1121 (2006).
15. Ehrlich P. Chemotherapeutics: scientific principles, methods and results. Lancet 1913, 445–451 (1913).
16. Blondeau J, Zhao X, Hansen GT, Drlica K. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433–438 (2001).
17. Hedlin P, Blondeau JM. Comparative minimal inhibitory and mutant prevention concentration (MPC) of gatifloxacin (GA) and other compounds against gram-positive ocular pathogens. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 25–29 April 2004 (Abstract 4919).
18. Blondeau JM, Hesje C, Blondeau LD, Borsos S. Determination of the mutant prevention concentration (MPC) for clinical isolates of Streptococcus pneumoniae (SP) with minimum inhibitory concentration (MIC) to azithromycin (AZ), clarithromycin (CL) and erythromycin (ER) of ≤0.125 mg/l. Presented at: 12th International Congress on Infectious Diseases (ICID). Lisbon, Portugal, 15–18 June 2006 (Abstract 29.053).
19. Blondeau JM, Tillotson GS. Comparative minimum inhibitory (MI) and mutant prevention (MP) drug concentrations (C) of gatifloxacin (Gat), gemifloxacin (Gem) and moxifloxacin (Mfx) against clinical isolates of Streptococcus pneumoniae (SP) with MICs to levofloxacin (Lfx) of ≥2 mg/l. Presented at: 12th International Congress on Infectious Diseases (ICID). Lisbon, Portugal, 15–18 June 2006 (Abstract 56.030).
20. Metzler KL, Borsos S, Blondeau JM. Application of the mutant prevention concentration (MPC) for Streptococcus pneumoniae (SP) against azithromycin (AZ), clarithromycin (CL) and erythromycin (ER). Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic, 1–4 May 2004 (Abstract P1744).
21. Blondeau JM, Borsos S, Hedlin P, Hansen G, Brandt M. Determination of the minimum inhibitory concentration and mutant prevention concentration of garenoxacin against over 500 clinical isolates of Streptococcus pneumoniae. Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 2–5 April 2005 (Abstract P.1211).
22. Blondeau JM, Drlica K, Hansen G, Zhao X. The mutant prevention concentration (MPC) of gemifloxacin against clinical isolates of Streptococcus pneumoniae (SP) that are susceptible (PS), intermediate (PI) or resistant (PR) to penicillin. Presented at: 7th International Symposium on New Quinolones. Edinburgh, Scotland, UK, 10–12 June 2001 (Abstract P81).
23. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int. J. Antimicrob. Agents 24, 150–160 (2004).
24. Blondeau JM, Metzler KL. Application of the resistance prevention concentration (RPC) to oxacillin (O), cefazolin (C) and vancomycin (C) against methicillin-susceptible (MS) and resistant (MR) Staphylococcus aureus (SA). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December 2005 (Abstract C2.297).
25. Wetzstein HG. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob. Agents Chemother. 49 (10), 4166–4173 (2005).
26. Hansen G, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 17 (5), 484–492 (2005).
27. Blondeau JM, Borsos S, Hesje C. Determination of the minimum inhibitory and mutant prevention concentrations of moxifloxacin against clinical isolates of E. coli and Klebsiella species. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, 31 March–3 April 2007 (Abstract P.1654).
28. Metzler KL, Hedlin P, Blondeau JM. Determination of minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC) of ocular isolates of Pseudomonas aeruginosa and Haemophilus influenzae to 5 fluoroquinolone antimicrobial agents. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 25–29 April 2004 (Abstract 4988).
29. Blondeau JM, Borsos S. Comparative minimum inhibitory concentration and mutant preveniton concentration of azithromycin, cefuroxime, gemifloxacin, moxifloxacin and telithromycin against clinical isolates of Haemophilus influenzae. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, 31 March–3 April 2007 (Abstract P-747).
30. Blondeau JM, Borsos S, Hesje C, Blondeau LD, Blondeau BJ. Comparative minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) values of enrofloxacin, florfenicol, tilmicosin and tulathromycin against Mannheimia haemolytica (MH) isolates collected from cattle and bovine respiratory disease. Presented at: International Meeting of Emerging Diseases and Surveillance (IMED). Vienna, Austria, 23–25 February 2007 (Abstract 04897).
31. Blondeau JM, Borsos S, Blondeau LD, Blondeau BJ, Hesje CK. Comparative minimum inhibitory and mutant prevention concentration of enrofloxacin against clinical isolates of Pasteurellae multocida (PM) and Mannheimia hemolytica (MH). Presented at: ASM Conference on Pasteurellaceae. Kona, Hawaii, 22–26 October 2005 (Abstract A125).